breast cancer
Conditions
Interventions
B:TEC
A:TEC+ Endostar
Sponsors
Hebei Medical University Fourth Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. women, more than 18 years, less than 70 years old; 2. from the core needle biopsy or Mammotome obtain pathology and relevant pathological data (ER, PR, C-erbB2, Ki-67, P53, pathological type, histological grade, not include the special type of breast cancer); 3. all the patients who accept the neoadjuvant chemotherapy (excluding patients with T0) should accord to NCCN Breast Cancer Clinical Practice Guidelines (China 2010); 4. Primary clinical lesions can be evaluated in patients' breast; 5. All the patients should be untreated: did not have any radiation therapy, drugs or surgery for breast cancer; 6. Routine examinations show no significant organ dysfunction and the patients can withstand chemotherapy and Endostar medication.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, liver or kidney dysfunction, poor physical fitness, more complications, or not suitable for the treatment of chemotherapy or Endostar should be exclused; 2. Allergy to the study drugs; 3. With previous history of bleeding disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological complete response rate (pCR);clinical efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| chemotherapy response rate of MP grade 4-5;side effects (including cardiac toxicity, hematology;DFS and OS; | — |
Countries
China
Contacts
Public ContactLiu Yunjiang
Outcome results
None listed